Price
CHART BY
Frequently asked questions
What is Filana Therapeutics, Inc.'s market capitalization?
The market capitalization of Filana Therapeutics, Inc. is $35.07M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Filana Therapeutics, Inc.?
Filana Therapeutics, Inc.'s Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.875. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Filana Therapeutics, Inc.'s stock?
Currently, 2 analysts cover Filana Therapeutics, Inc.'s stock, with a consensus target price of $6.50. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Filana Therapeutics, Inc.?
Filana Therapeutics, Inc.'s Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$44.86M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Filana Therapeutics, Inc.?
Filana Therapeutics, Inc. has a free cash flow of -$29.30M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Filana Therapeutics, Inc. have, and what sector and industry does it belong to?
Filana Therapeutics, Inc. employs approximately 20 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Filana Therapeutics, Inc.'s shares?
The free float of Filana Therapeutics, Inc. is 47.32M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $35.07M
- EPS (TTM)
- -$0.875
- Free Float
- 47.32M
- EBITDA (TTM)
- -$44.86M
- Free Cashflow (TTM)
- -$29.30M
Pricing
- 1D span
- $0.708$0.736
- 52W span
- $0.674$4.97
Analyst Ratings
The price target is $6.50 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
- Employees
- 20
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- SAVA
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet